Showing results (261-270 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 12, 2019
Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenylsGabriel Daragan, Jenny Hoffmann, Theresa Vasko, et al.
Investigational New Drugs|April 26, 2019
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinomaGlen J Weiss, Lisa Blaydorn, Julia Beck, et al.
Investigational New Drugs|April 13, 2019
Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34aJianguo Bai, Jianfei Wu, Ruifeng Tang, et al.
Investigational New Drugs|April 27, 2019
Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trialKenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, et al.
Investigational New Drugs|April 30, 2019
Correction to: Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathwayPiming Zhao, Ana E Aguilar, Joanna Y Lee, et al.
Investigational New Drugs|July 30, 2018
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumorsKathleen N Moore, Johanna C Bendell, Patricia M LoRusso, et al.
Investigational New Drugs|August 4, 2018
A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2Hui Huang, Junxing Niu, Fei Wang, et al.
Investigational New Drugs|July 5, 2018
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion proteinTakahisa Kawamura, Haruyasu Murakami, Haruki Kobayashi, et al.
Investigational New Drugs|July 23, 2018
Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjectsZhi-Yi Zhang, Jing Wang, Vikram Kansra, et al.
Investigational New Drugs|June 28, 2018
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) studyManuel Ruiz-Borrego, Begoña Jimenez, Silvia Antolín, et al.
Pageof 372